Inflammatory mediators and catabolic enzymes

Inflammatory mediators and catabolic enzymes refers to a broad functional group of molecules that drive the inflammatory process and the degradation of tissue structures, particularly the extracellular matrix. Inflammatory mediators include cytokines such as Tumor necrosis factor-alpha (TNF-alpha) and Interleukin-1 beta (IL-1 beta), as well as lipid-derived mediators like prostaglandins, which serve as primary signals for immune activation and pain (StatPearls, 2023). These mediators stimulate the production of catabolic enzymes, most notably Matrix metalloproteinases (MMPs) and Aggrecanases (ADAMTS), which catalyze the breakdown of collagen and proteoglycans (UniProt, 2024). This pathological cascade is central to the progression of chronic inflammatory and degenerative conditions, such as Rheumatoid arthritis and Osteoarthritis, where the balance between tissue synthesis and degradation is lost (PubMed, 2022). Therapeutic strategies often involve the use of biologics to neutralize specific cytokines or small molecule inhibitors to block the activity of enzymes like Cyclooxygenase-2 (COX-2) (PubChem, 2024). Because this term groups together numerous distinct proteins and pathways, it is classified as a broad category of therapeutic interests rather than a single molecular target.

Other names

Pro-inflammatory cytokines and proteasesDegradative enzymes and inflammatory factorsInflammatory signaling moleculesCatabolic factors

Drugs targeting these components work by neutralizing pro-inflammatory cytokines, blocking their respective receptors, or inhibiting the catalytic activity of enzymes responsible for tissue degradation and prostaglandin synthesis.